Pacific Shuanglin Bio pharmacy Co Ltd
Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in research, development, production, and sales of blood products in China and internationally. The company offers human serum albumin, intravenous human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus and anti-tetanus human immunoglobulin, rabies patient immunoglobulin, human c… Read more
Pacific Shuanglin Bio pharmacy Co Ltd - Asset Resilience Ratio
Pacific Shuanglin Bio pharmacy Co Ltd (000403) has an Asset Resilience Ratio of 6.88% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1996–2024)
This chart shows how Pacific Shuanglin Bio pharmacy Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Pacific Shuanglin Bio pharmacy Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥658.87 Million | 6.88% |
| Total Liquid Assets | CN¥658.87 Million | 6.88% |
Asset Resilience Insights
- Limited Liquidity: Pacific Shuanglin Bio pharmacy Co Ltd maintains only 6.88% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Pacific Shuanglin Bio pharmacy Co Ltd Industry Peers by Asset Resilience Ratio
Compare Pacific Shuanglin Bio pharmacy Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF |
Biotechnology | 25.67% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Exicure Inc
NASDAQ:XCUR |
Biotechnology | 0.00% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
Annual Asset Resilience Ratio for Pacific Shuanglin Bio pharmacy Co Ltd (1996–2024)
The table below shows the annual Asset Resilience Ratio data for Pacific Shuanglin Bio pharmacy Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.06% | CN¥282.70 Million | CN¥9.25 Billion | -1.85pp |
| 2023-12-31 | 4.91% | CN¥423.34 Million | CN¥8.63 Billion | -0.39pp |
| 2022-12-31 | 5.29% | CN¥422.44 Million | CN¥7.98 Billion | +1.99pp |
| 2021-12-31 | 3.30% | CN¥234.21 Million | CN¥7.09 Billion | +2.93pp |
| 2017-12-31 | 0.38% | CN¥5.00 Million | CN¥1.32 Billion | +0.37pp |
| 2010-12-31 | 0.01% | CN¥50.10K | CN¥925.41 Million | +0.00pp |
| 2009-12-31 | 0.00% | CN¥47.45K | CN¥1.25 Billion | +0.00pp |
| 2008-12-31 | 0.00% | CN¥28.10K | CN¥1.21 Billion | -0.10pp |
| 2007-12-31 | 0.10% | CN¥1.69 Million | CN¥1.66 Billion | +0.07pp |
| 2006-12-31 | 0.03% | CN¥566.03K | CN¥1.71 Billion | 0.00pp |
| 2005-12-31 | 0.03% | CN¥716.11K | CN¥2.08 Billion | -0.06pp |
| 2004-12-31 | 0.10% | CN¥2.05 Million | CN¥2.12 Billion | -0.43pp |
| 2003-12-31 | 0.53% | CN¥11.86 Million | CN¥2.24 Billion | +0.44pp |
| 2002-12-31 | 0.09% | CN¥1.34 Million | CN¥1.54 Billion | -4.33pp |
| 1996-12-31 | 4.42% | CN¥14.62 Million | CN¥330.76 Million | -- |